Key points from article :
Moonwalk Biosciences received $57 million to develop therapies by reprogramming cells with "read-and-write" epigenetic technologies.
They target the epigenome, the chemical "software" of genes, by analysing DNA methylation patterns and using tools to alter them, unlike gene editing that changes the DNA sequence itself.
Moonwalk claims this approach avoids disrupting the original DNA and allows precise control over multiple genes, potentially creating safer and more effective treatments.
They're exploring this technology to potentially reverse diseases and even address age-related decline by identifying and reversing epigenetic changes linked to loss of cell function.
The new funding will help advance their platform and potential therapies towards clinical trials, with the goal of filing Investigational New Drug (IND) applications within the next three years.
Renowned investors like Alpha Wave Global and ARCH Venture Partners support Moonwalk, recognising the potential of their platform to address complex diseases through precise epigenetic engineering.
